secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2024-04-12T23:59:59+00:00
Accession:  0001558370-24-004997
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune-Genentech allogeneic T-cell collaboration terminated; focus on afami-cel PDUFA Aug 4
--------------------------------------------------------------------------------

- Genentech terminates 2021 collaboration on allogeneic T-cell therapies; termination effective ~Oct 7, 2024.
- Adaptimmune received $150M upfront and $35M milestones; no further milestones or payments due.
- Company reaffirms focus on afami-cel launch; PDUFA target date August 4, 2024; Investor Day April 18.
- Adaptimmune retains all rights to its iPSC-based allogeneic platform and autologous pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/0001558370-24-004997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/adap-20240410x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer